


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:35Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406429" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406429</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>jmedcasrep</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Med Case Rep</journal-id><journal-id journal-id-type="pmc-domain-id">476</journal-id><journal-id journal-id-type="pmc-domain">jmedcasrep</journal-id><journal-title-group><journal-title>Journal of Medical Case Reports</journal-title></journal-title-group><issn pub-type="epub">1752-1947</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406429</article-id><article-id pub-id-type="pmcid-ver">PMC12406429.1</article-id><article-id pub-id-type="pmcaid">12406429</article-id><article-id pub-id-type="pmcaiid">12406429</article-id><article-id pub-id-type="pmid">40898267</article-id><article-id pub-id-type="doi">10.1186/s13256-025-05332-w</article-id><article-id pub-id-type="publisher-id">5332</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>A CSPP1 variant associated with metabolic dysfunction in Joubert syndrome: a case report</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Acosta-Paguada</surname><given-names initials="LF">Liany F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vel&#225;squez-Hernandez</surname><given-names initials="MS">Milca S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bonilla Medina</surname><given-names initials="PS">Paola Sophia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0991-8179</contrib-id><name name-style="western"><surname>Perdomo Dom&#237;nguez</surname><given-names initials="ES">Eduardo Smelin</given-names></name><address><email>es_perdomod@unicah.edu</email><email>edupe1007@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>Faculty of Medicine, Catholic University of Honduras, San Pedro Sula, Honduras </aff><aff id="Aff2"><label>2</label>Pediatric Endocrinologist, Hospital Benda&#241;a, San Pedro Sula, Honduras </aff><aff id="Aff3"><label>3</label>Pediatric Endocrinologist, Hospital Mario Catarino Rivas, San Pedro Sula, Honduras </aff><aff id="Aff4"><label>4</label>GIMUNICAH, Faculty of Medicine, Catholic University of Honduras, San Pedro Sula, Honduras </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">478511</issue-id><elocation-id>438</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13256_2025_Article_5332.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Joubert syndrome is a genetically heterogeneous ciliopathy characterized by cerebellar vermis hypoplasia and the distinctive molar tooth sign on neuroimaging, often accompanied by neurological impairment. Pathogenic CSPP1 variants account for approximately 3% of Joubert syndrome cases. While certain ciliopathies have been associated with metabolic dysfunction, this has not been described in CSPP1-related Joubert syndrome. </p></sec><sec><title>Case presentation</title><p id="Par2">We report a 16-year-old Honduran mestiza female patient with CSPP1-related Joubert syndrome who presented with insulin resistance, early onset diabetes, dyslipidemia, and metabolic dysfunction-associated steatotic liver disease. Notably, she lacked the typical neurological symptoms of Joubert syndrome. Brain magnetic resonance imaging revealed cerebellar vermis hypoplasia, confirming the diagnosis. Genetic testing identified a pathogenic heterozygous CSPP1 variant (c.3052C&#8201;&gt;&#8201;T, p.Gln1018), supporting the diagnosis of CSPP1-related Joubert syndrome. </p></sec><sec><title>Conclusion</title><p id="Par3">This case expands the phenotypic spectrum of CSPP1-related Joubert syndrome and raises the possibility of a role for CSPP1 in metabolic homeostasis. Further research is needed to determine whether CSPP1 mutations contribute to metabolic dysfunction via ciliary or centrosome-associated mechanisms.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Case report</kwd><kwd>Joubert syndrome</kwd><kwd>CSPP1</kwd><kwd>Diabetes</kwd><kwd>Ciliopathy</kwd><kwd>Primary cilium</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par9">Joubert syndrome (JS; #OMIM 213300) is a genetically heterogeneous disorder characterized by cerebellar vermis hypoplasia and the distinctive &#8220;molar tooth sign&#8221; on neuroimaging, often accompanied by motor dysfunction and cognitive impairments. More than 40 causative genes have been identified, all encoding proteins essential for primary cilium function [<xref ref-type="bibr" rid="CR1">1</xref>]. Pathogenic variants in CPLANE1, CC2D2A, AHI1, CEP290, and TMEM67 each account for&#8201;~6&#8211;9% of JS cases, while CSPP1 variants are responsible for approximately 3% of JS cases, highlighting the challenge of establishing clear genotype&#8211;phenotype correlations [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par10">Although JS is primarily neurological, it can also present with multisystem involvement, including kidney and liver disease, retinal dystrophy, chorioretinal colobomas, occipital encephalocele, and polydactyly, reflecting its broad clinical spectrum [<xref ref-type="bibr" rid="CR3">3</xref>]. While metabolic dysfunction is not a recognized feature of CSPP1-related JS, ciliopathies have been linked to systemic metabolic disturbances.</p><p id="Par11">We describe the case of a 16-year-old female patient with a novel pathogenic CSPP1 variant (c.3052C&#8201;&gt;&#8201;T, p.Gln1018) who exhibited metabolic dysfunction, including insulin resistance, early onset diabetes, dyslipidemia, and metabolic dysfunction-associated steatotic liver disease (MASLD) in the absence of neurological symptoms typically associated with JS. This case expands the phenotypic spectrum of CSPP1-related JS, suggesting a potential role of CSPP1 in metabolic regulation.</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par12">We report the case of a Honduran mestiza 16-year-old girl born to non-consanguineous parents. She is the youngest of three siblings, born to a 31-year-old mother and a 41-year-old father. The pregnancy was uncomplicated, and there was no known exposure to teratogenic drugs, infections, or radiation. The patient was born via spontaneous vaginal delivery with a birth weight of 1.81&#160;kg. Her developmental milestones were unremarkable. However, at 2 years of age, she began experiencing progressive fat loss. Menarche occurred at the age of 11 years. Her menstrual cycles were irregular, with menstrual bleeding lasting up to 15&#160;days. Family history was significant for maternal hypertension and total thyroidectomy due to hypothyroidism. Her father, who also had hypertension, passed away at 57&#160;years old due to lung cancer. Additionally, second-degree maternal relatives had a history of diabetes and hypertension. She was previously evaluated by pediatric cardiology due to recurrent episodes of tachycardia. Blood pressure measurement revealed hypertension (150/95&#160;mmHg), and ambulatory blood pressure monitoring confirmed arterial hypertension. Transthoracic echocardiography demonstrated moderate left ventricular hypertrophy, with a left ventricular end-diastolic diameter of 42&#160;mm and a left ventricular ejection fraction of 59.1%. Evaluation for secondary causes of hypertension was performed. Serum electrolytes revealed sodium of 131&#160;mEq/L, potassium of 4.1&#160;mEq/L, and chloride of 99&#160;mEq/L. Serum calcium was 9.5&#160;mg/dL and phosphorus was 3.9&#160;mg/dL. Parathyroid hormone level was 17.7&#160;pg/mL, and 24-h urinary cortisol was 37.57&#160;&#181;g/24&#160;h. These findings were within normal ranges, and the renal Doppler ultrasound was unremarkable. She was started on amlodipine for blood pressure management.</p><p id="Par13">Due to suspected thyroid dysfunction, she was referred to pediatric endocrinology for further evaluation. On clinical examination, the patient exhibited prominent supraorbital ridges, generalized lipoatrophy, and acanthosis nigricans at the neck, axillae, wrist, and groin (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Anthropometric measurements revealed a weight of 36.5&#160;kg (third percentile, &#8722;2.00 SD), height of 154&#160;cm (ninth percentile, &#8722;1.38 SD), and a body mass index (BMI) of 15.39&#160;kg/m<sup>2</sup> (fourth percentile, &#8722;1.82 SD). A thyroid Doppler ultrasound showed normal thyroid size and shape with a diffuse heterogeneous echogenicity. Thyroid function tests revealed a free thyroxine of 1.0&#160;ng/dL and a thyroid-stimulating hormone of 0.575&#160;mIU/L. Markers of autoimmune thyroid disease including thyroid stimulating immunoglobulin, thyroid peroxidase antibody, and thyroglobulin antibody were negative. Serum estradiol was 73.10&#160;pg/mL, luteinizing hormone 8.58&#160;mIU/mL, follicle-stimulating hormone 5.70&#160;mIU/mL, and free testosterone 4.1&#160;pg/mL.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Clinical features of patient with Joubert syndrome associated with a novel CSPP1 variant; (<bold>A</bold>) generalized lipoatrophy, (<bold>B</bold>) acanthosis nigricans in the axilla, (<bold>C</bold>) acanthosis nigricans on the wrist</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="13256_2025_5332_Fig1_HTML.jpg"/></fig></p><p id="Par14">Further investigation revealed fasting blood glucose of 268&#160;mg/dL, glycosylated hemoglobin (HbA1c) of 12.1%, fasting insulin levels of 78.4&#160;&#181;U/mL, C-peptide levels of 5.37&#160;ng/mL, serum creatinine of 0.6&#160;mg/dL, and an estimated glomerular filtration rate (eGFR) of 106&#160;mL/min/1.73&#160;m<sup>2</sup>. Lipid profile showed triglycerides of 459&#160;mg/dL, total cholesterol of 237&#160;mg/dL, high-density lipoprotein (HDL) levels of 39&#160;mg/dL, and low-density lipoprotein (LDL) of 99&#160;mg/dL. Liver function tests demonstrated aspartate aminotransferase (AST) levels of 58&#160;U/L and alanine aminotransferase (ALT) levels of 117&#160;U/L. Total bilirubin was 0.80&#160;mg/dL, with a direct bilirubin of 0.18&#160;mg/dL and an indirect bilirubin of 0.62&#160;mg/dL. Hepatitis B surface antigen testing was negative. These laboratory findings, along with follow-up data, are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Summary of initial and follow-up laboratory findings in a patient with CSPP1-related Joubert syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Initial evaluation</th><th align="left" colspan="1" rowspan="1">First follow-up</th><th align="left" colspan="1" rowspan="1">Second follow-up</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Electrolytes</td><td align="left" colspan="1" rowspan="1">Na: 131/K: 4.1/Cl: 99 (mEq/L)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Calcium and phosphorus</td><td align="left" colspan="1" rowspan="1">Ca: 9.5/P: 3.9 (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Endocrine evaluation</td><td align="left" colspan="1" rowspan="1">PTH: 17.7 (pg/mL); 24&#160;h urinary cortisol: 37.57 (&#181;g/24&#160;h)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Renal function</td><td align="left" colspan="1" rowspan="1">Creatinine: 0.6 (mg/dL); eGFR: 106 (mL/min/1.73&#160;m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">Creatinine: 0.5 (mg/dL); eGFR: 128 (mL/min/1.73&#160;m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Thyroid function</td><td align="left" colspan="1" rowspan="1">Free T4: 1.0 (ng/dL); TSH: 0.575 (mIU/L)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Autoimmune thyroid markers</td><td align="left" colspan="1" rowspan="1">Negative</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Glucose metabolism</td><td align="left" colspan="1" rowspan="1">FG: 268 (mg/dL); HbA1c: 12.1%; insulin: 78.4 (&#181;U/mL); C-peptide: 5.37 (ng/mL)</td><td align="left" colspan="1" rowspan="1">FG: 266 (mg/dL); HbA1c: 11%</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid profile</td><td align="left" colspan="1" rowspan="1">TC: 237/TG: 459/HDL: 39/LDL: 99 (mg/dL)</td><td align="left" colspan="1" rowspan="1">TC: 277/TG: 298 (mg/dL)</td><td align="left" colspan="1" rowspan="1">TC: 304/TG: 855 (mg/dL)</td></tr><tr><td align="left" colspan="1" rowspan="1">Liver function</td><td align="left" colspan="1" rowspan="1">AST: 58/ALT: 117 (U/L)</td><td align="left" colspan="1" rowspan="1">AST: 66/ALT: 109 (U/L)</td><td align="left" colspan="1" rowspan="1">AST: 155/ALT: 228 (U/L)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bilirubins</td><td align="left" colspan="1" rowspan="1">Total: 0.80/direct: 0.18/indirect: 0.62 (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Hepatitis screening</td><td align="left" colspan="1" rowspan="1">HBsAg: negative</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Leptin</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2.1 (ng/mL)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Autoantibodies (diabetes)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">GAD-65 and islet cell antibodies: negative</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">PTH</italic> parathyroid hormone, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate, <italic toggle="yes">T4</italic> thyroxine, <italic toggle="yes">TSH</italic> thyroid-stimulating hormone, <italic toggle="yes">FG</italic> fasting glucose, <italic toggle="yes">HbA1c</italic> glycosylated hemoglobin, <italic toggle="yes">TC</italic> total cholesterol, <italic toggle="yes">TG</italic> triglycerides, <italic toggle="yes">HDL</italic> high-density lipoprotein, <italic toggle="yes">LDL</italic> low-density lipoprotein, <italic toggle="yes">AST</italic> aspartate aminotransferase, <italic toggle="yes">ALT</italic> alanine aminotransferase, <italic toggle="yes">HBsAg</italic> hepatitis B surface antigen</p></table-wrap-foot></table-wrap></p><p id="Par15">Abdominal ultrasound showed hepatomegaly with a diffuse increase in echogenicity, while both kidneys were normal in size, position, and echotexture (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). She was immediately started on insulin degludec (18 units). Fenofibrate treatment (160&#160;mg daily) was initiated along with omega-3 supplementation. The management of diabetes and dyslipidemia was conducted in accordance with the American Diabetes Association Standards of Medical Care in Diabetes and the American College of Cardiology guidelines.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Abdominal ultrasound showing hepatomegaly with a diffuse increase in hepatic echogenicity. Labels in the image correspond to the right (HIG LOB DER) and left (HIG LOB IZQ) hepatic lobes</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="13256_2025_5332_Fig2_HTML.jpg"/></fig></p><p id="Par16">At the 1-month follow-up visit, insulin therapy was adjusted with the initiation of aspart insulin at 7&#8211;7-6 units before meals. Fasting blood glucose was 266&#160;mg/dL, and HbA1c was 11%. Lipid profile showed total cholesterol of 277&#160;mg/dL and triglycerides of 298&#160;mg/dL. Liver function tests demonstrated AST at 66&#160;U/L and ALT at 109&#160;U/L. Serum creatinine was 0.5&#160;mg/dL, with an eGFR of 128&#160;mL/min/1.73&#160;m<sup>2</sup>. Leptin level was 2.1&#160;ng/mL. Metformin was initiated at 500&#160;mg twice a day. Vitamin E was added to the regimen, omega-3 supplementation was continued, and combined lipid-lowering therapy with rosuvastatin and fenofibrate was initiated.</p><p id="Par17">Subsequently, the dose of insulin degludec was increased to 23 units. Anti-GAD-65 and anti-islet cell antibodies were negative. At the following visit, insulin therapy was further adjusted to 30 units, along with aspart insulin at 10&#8211;10-10 units before meals and metformin at 1000&#160;mg daily. Lipid-lowering therapy was modified to atorvastatin/fenofibrate (20/160&#160;mg) due to elevated triglycerides (855&#160;mg/dL) and total cholesterol (304&#160;mg/dL). Given persistently elevated AST (155 U/L) and ALT (228 U/L), vitamin E and omega-3 supplementation were continued.</p><p id="Par18">Genetic testing using a comprehensive 616-gene panel identified a pathogenic heterozygous variant in CSPP1 (c.3052C&#8201;&gt;&#8201;T, p.Gln1018), associated with autosomal recessive JS and related disorders (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Additionally, five variants of uncertain significance were detected in DLC1 (c.1826C&#8201;&gt;&#8201;G, p.Pro609Arg), FBN3 (c.853G&#8201;&gt;&#8201;A, p.Ala285Thr), GATA3 (c.724G&#8201;&gt;&#8201;C, p.Gly242Arg), and SRCAP (c.8747C&#8201;&gt;&#8201;T, p.Pro2916Leu). Two benign variants classified as pseudodeficiency alleles were also identified in GALC (c.1685&#160;T&#8201;&gt;&#8201;C, p.Ile562Thr and c.550C&#8201;&gt;&#8201;T, p.Arg184Cys). Brain magnetic resonance imaging (MRI) confirmed hypoplasia of the cerebellar vermis, consistent with JS (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Ophthalmologic evaluation revealed bilateral astigmatism and myopia in the left eye. Imaging findings are summarized in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Integrative Genomics Viewer showing the heterozygous c.3052C&#8201;&gt;&#8201;T (p.Gln1018) variant in CSPP1 </p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="13256_2025_5332_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Brain magnetic resonance imaging findings; (<bold>A</bold>) axial T1-weighted magnetic resonance imaging showing no evidence of the classic &#8220;molar tooth sign,&#8221; (<bold>B</bold>) sagittal T1-weighted magnetic resonance imaging demonstrating cerebellar vermis hypoplasia (white arrow)</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="13256_2025_5332_Fig4_HTML.jpg"/></fig><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Summary of imaging findings in patient with CSPP1-related Joubert syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Imaging study</th><th align="left" colspan="1" rowspan="1">Findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Transthoracic echocardiography</td><td align="left" colspan="1" rowspan="1">Moderate left ventricular hypertrophy; LVEF of 59.1%</td></tr><tr><td align="left" colspan="1" rowspan="1">Abdominal USG</td><td align="left" colspan="1" rowspan="1">Hepatomegaly with diffuse increased echogenicity; kidneys normal in size, position, and echotexture</td></tr><tr><td align="left" colspan="1" rowspan="1">Thyroid Doppler USG</td><td align="left" colspan="1" rowspan="1">Normal thyroid size and shape with diffuse heterogeneous echogenicity</td></tr><tr><td align="left" colspan="1" rowspan="1">Renal Doppler USG</td><td align="left" colspan="1" rowspan="1">No evidence of renal artery stenosis or abnormalities</td></tr><tr><td align="left" colspan="1" rowspan="1">Brain MRI</td><td align="left" colspan="1" rowspan="1">Hypoplasia of the cerebellar vermis</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LVEF</italic> left ventricular ejection fraction, <italic toggle="yes">MRI</italic> magnetic resonance imaging, <italic toggle="yes">USG</italic> ultrasound</p></table-wrap-foot></table-wrap></p><p id="Par19">Due to failure of achieving glycemic control, insulin therapy was transitioned to a combination regimen with insulin glargine-lixisenatide at an initial dose of 23 units, later increased to 30 units, while aspart insulin was adjusted to 8&#8211;8-7 units before meals.</p></sec><sec id="Sec3"><title>Discussion and conclusion</title><p id="Par20">We describe a 16-year-old female patient with a novel pathogenic CSPP1 variant (c.3052C&#8201;&gt;&#8201;T, p.Gln1018), presenting with metabolic dysfunction characterized by insulin resistance, early onset diabetes, dyslipidemia, and MASLD. Despite the presence of cerebellar vermis hypoplasia on brain MRI, she exhibited no neurological symptoms or developmental delay, which contrasts with typical CSPP1-related JS (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Schematic representation of clinical features associated with the CSPP1 variant (c.3052C&#8201;&gt;&#8201;T, p.Gln1018)</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="13256_2025_5332_Fig5_HTML.jpg"/></fig></p><p id="Par21">JS is a heterogeneous disorder with a broad spectrum of neurological manifestations, ranging from early onset features such as neonatal hypotonia, abnormal eye movements, and developmental delay to later-onset symptoms including cerebellar ataxia and cognitive impairment. CSPP1 variants have been identified in approximately 9% of purely neurological JS cases [<xref ref-type="bibr" rid="CR2">2</xref>]. However, despite the presence of cerebellar vermis hypoplasia, our patient exhibited no motor or cognitive impairments, further highlighting the phenotypic variability of CSPP1-related JS.</p><p id="Par22">While CSPP1 has been associated with retinopathy, this finding has been reported in a minority of cases, with one study identifying it in only four out of 31 CSPP1-related patients with JS [<xref ref-type="bibr" rid="CR4">4</xref>]. Additionally, CSPP1 mutations have been linked to optic atrophy, nystagmus, oculomotor apraxia, and ptosis, the latter observed in 51% of patients with JS with CSPP1 variants [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Our patient exhibited only myopia and astigmatism, with no evidence of retinopathy or other ocular findings.</p><p id="Par23">Genotype&#8211;phenotype correlation in CSPP1 and other ciliopathies remains a challenge, as seen in genes such as RPGRIP1L, MKS1, CPLANE1, CEP290, and TMEM231, where identical variants can result in clinically diverse phenotypes [<xref ref-type="bibr" rid="CR7">7</xref>]. CSPP1 is crucial for ciliary function rather than ciliogenesis, affecting ciliary length, stability, and protein trafficking [<xref ref-type="bibr" rid="CR8">8</xref>]. Disruption of these functions has been linked to JS and Jeune asphyxiating thoracic dystrophy, but its impact on metabolic homeostasis has not been previously described. Given that other ciliopathies, such as Alstr&#246;m syndrome, exhibit insulin resistance and dyslipidemia, CSPP1 may also play a role in metabolism-related pathways [<xref ref-type="bibr" rid="CR9">9</xref>]. Unlike previously reported cases of JS with hepatic involvement, which are often associated with hepatic fibrosis, our patient exhibited elevated transaminases in the context of metabolic dysfunction rather than structural liver disease. The presence of insulin resistance and dyslipidemia suggests that the hepatic abnormalities observed in this case are more likely due to metabolic dysfunction rather than a ciliopathy-related hepatic phenotype. This further supports the hypothesis that CSPP1 may influence metabolic processes beyond its known neurological and developmental functions.</p><p id="Par24">Although a case of JS with type 1 diabetes has been reported, our patient&#8217;s phenotype suggests a distinct mechanism, independent of autoimmunity [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par25">Additionally, growing evidence suggests that centrosomal proteins may contribute to metabolic homeostasis. Pericentrin, another centrosomal protein, has been associated with severe insulin resistance and dyslipidemia, supporting the idea that disruptions in centrosome- and cilia-associated proteins can influence metabolic regulation [<xref ref-type="bibr" rid="CR9">9</xref>]. The metabolic phenotype observed in our patient, in the absence of neurological clinical features, suggests that CSPP1 mutations may selectively impact centrosome- and cilia-mediated processes in peripheral tissues.</p><p id="Par26">Although JS is classically inherited in an autosomal recessive manner, including cases related to CSPP1, evidence suggests that heterozygous pathogenic variants may also contribute to JS-like phenotypes. Some reports have described patients with <italic toggle="yes">de&#160;novo</italic> heterozygous pathogenic variants in SLC30A7, CHD7, and SUFU genes, presenting with classical or mild features of Joubert syndrome [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. In our case, only a single heterozygous pathogenic variant in CSPP1 was identified, without detection of a second pathogenic allele. While this finding raises the possibility of a mild or atypical manifestation within JS, we acknowledge that cryptic second hits, such as copy number variants or deep intronic mutations, could not be excluded. In patients initially identified with only one pathogenic heterozygous variant, a second cryptic mutation has been uncovered in approximately 54% of cases after focused reanalysis of exome sequencing data [<xref ref-type="bibr" rid="CR14">14</xref>]. Thus, while the heterozygous CSPP1 variant strongly supports the diagnosis, further genetic investigation would be necessary to establish a definitive causal relationship.</p><p id="Par27">Several alternative factors may contribute to the metabolic phenotype observed in our patient. First, the family history of diabetes among second-degree maternal relatives may modestly increase her baseline risk for metabolic dysfunction. Previous studies have shown that individuals with two or more second-degree relatives affected by type 2 diabetes have an approximately 1.36-fold increased risk compared with those without such a family history [<xref ref-type="bibr" rid="CR15">15</xref>]. Second, the patient&#8217;s low birth weight (1.81&#160;kg) may independently predispose her to later metabolic complications. A recent meta-analysis demonstrated that individuals born with a weight under 2.5&#160;kg have a 45% higher risk of developing type 2 diabetes, with a stronger association observed among female individuals. [<xref ref-type="bibr" rid="CR16">16</xref>] Third, the presence of generalized lipoatrophy, together with severe insulin resistance, early onset diabetes, and dyslipidemia suggests a possible contribution of a lipodystrophic process to the metabolic phenotype. However, no pathogenic variants were identified in genes classically associated with congenital generalized lipodystrophy, such as AGPAT2 or BSCL2, suggesting that alternative or syndromic mechanisms may be involved.</p><p id="Par28">Additional genetic variants identified in our patient, including variants of uncertain significance in DLC1, FBN3, GATA3, and SRCAP, were reviewed critically. None of these variants have established pathogenicity, and their preliminary associations do not correlate with the patient&#8217;s clinical features, particularly the presence of metabolic dysfunction. Therefore, the observed clinical phenotype remains most consistent with a primary defect related to the CSPP1 pathogenic variant.</p><p id="Par29">Genetic analysis was performed on the patient only, without parental testing. Therefore, we were unable to determine whether the CSPP1 variant identified is <italic toggle="yes">de&#160;novo</italic> or inherited.</p><p id="Par30">This case expands the phenotypic spectrum of CSPP1-related JS and suggests a potential novel role of CSPP1 in metabolic homeostasis. Further functional studies are needed to determine whether CSPP1 modulates intracellular signaling in metabolic tissues and its potential interactions with key regulatory pathways in energy balance.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>JS</term><def><p id="Par4">Joubert syndrome</p></def></def-item><def-item><term>eGFR</term><def><p id="Par5">Estimated glomerular filtration rate</p></def></def-item><def-item><term>HbA1c</term><def><p id="Par6">Glycosylated hemoglobin</p></def></def-item><def-item><term>MASLD</term><def><p id="Par7">Metabolic dysfunction-associated steatotic liver disease</p></def></def-item><def-item><term>MRI</term><def><p id="Par8">Magnetic resonance imaging</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>LFAP: conceptualization, data curation, writing&#8212;original draft, and writing&#8212;review and editing. MSVH: conceptualization, data curation, writing&#8212;original draft, and writing&#8212;review and editing. PSBM: conceptualization and data curation. ESPD: conceptualization, supervision, writing&#8212;original draft, and writing&#8212;review and editing. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funding was obtained for this article.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par31">Informed consent was obtained from the patient&#8217;s legal representative, and all procedures were performed according to the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par32">Written informed consent was obtained from the patient&#8217;s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par33">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiter</surname><given-names>JF</given-names></name><name name-style="western"><surname>Leroux</surname><given-names>MR</given-names></name></person-group><article-title>Genes and molecular pathways underpinning ciliopathies</article-title><source>Nat Rev Mol Cell Biol</source><year>2017</year><volume>18</volume><fpage>533</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">28698599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm.2017.60</pub-id><pub-id pub-id-type="pmcid">PMC5851292</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Reiter JF, Leroux MR. Genes and molecular pathways underpinning ciliopathies. Nat Rev Mol Cell Biol. 2017;18:533&#8211;47.<pub-id pub-id-type="pmid">28698599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm.2017.60</pub-id><pub-id pub-id-type="pmcid">PMC5851292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann-Gagescu</surname><given-names>R</given-names></name><name name-style="western"><surname>Dempsey</surname><given-names>JC</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>IG</given-names></name><name name-style="western"><surname>O&#8217;Roak</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Knutzen</surname><given-names>DM</given-names></name><name name-style="western"><surname>Rue</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Joubert syndrome: a model for untangling recessive disorders with extreme genetic heterogeneity</article-title><source>J Med Genet</source><year>2015</year><volume>52</volume><fpage>514</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">26092869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2015-103087</pub-id><pub-id pub-id-type="pmcid">PMC5082428</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bachmann-Gagescu R, Dempsey JC, Phelps IG, O&#8217;Roak BJ, Knutzen DM, Rue TC, <italic toggle="yes">et&#160;al</italic>. Joubert syndrome: a model for untangling recessive disorders with extreme genetic heterogeneity. J Med Genet. 2015;52:514&#8211;22.<pub-id pub-id-type="pmid">26092869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2015-103087</pub-id><pub-id pub-id-type="pmcid">PMC5082428</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilboux</surname><given-names>T</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>DA</given-names></name><name name-style="western"><surname>Glass</surname><given-names>IA</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>IG</given-names></name><name name-style="western"><surname>Cullinane</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Molecular genetic findings and clinical correlations in 100 patients with Joubert syndrome and related disorders prospectively evaluated at a single center</article-title><source>Genet Med</source><year>2017</year><volume>19</volume><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">28125082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2016.204</pub-id><pub-id pub-id-type="pmcid">PMC11528337</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Vilboux T, Doherty DA, Glass IA, Parisi MA, Phelps IG, Cullinane AR, <italic toggle="yes">et&#160;al</italic>. Molecular genetic findings and clinical correlations in 100 patients with Joubert syndrome and related disorders prospectively evaluated at a single center. Genet Med. 2017;19:875&#8211;82.<pub-id pub-id-type="pmid">28125082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2016.204</pub-id><pub-id pub-id-type="pmcid">PMC11528337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Fu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>B</given-names></name></person-group><article-title>Novel compound heterozygous variants in the CSPP1 gene causes Joubert syndrome: case report and literature review of the CSPP1 gene&#8217;s pathogenic mechanism</article-title><source>Front Pediatr</source><year>2024</year><volume>12</volume><fpage>1305754</fpage><pub-id pub-id-type="pmid">38586154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2024.1305754</pub-id><pub-id pub-id-type="pmcid">PMC10995352</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wei C, Zhang H, Fu M, Ye J, Yao B. Novel compound heterozygous variants in the CSPP1 gene causes Joubert syndrome: case report and literature review of the CSPP1 gene&#8217;s pathogenic mechanism. Front Pediatr. 2024;12:1305754.<pub-id pub-id-type="pmid">38586154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2024.1305754</pub-id><pub-id pub-id-type="pmcid">PMC10995352</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>BP</given-names></name><name name-style="western"><surname>Zein</surname><given-names>WM</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AH</given-names></name><name name-style="western"><surname>Mokhtarzadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>DA</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Joubert syndrome: ophthalmological findings in correlation with genotype and hepatorenal disease in 99 patients prospectively evaluated at a single center</article-title><source>Ophthalmology</source><year>2018</year><volume>125</volume><fpage>1937</fpage><lpage>1952</lpage><pub-id pub-id-type="pmid">30055837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2018.05.026</pub-id><pub-id pub-id-type="pmcid">PMC8932443</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Brooks BP, Zein WM, Thompson AH, Mokhtarzadeh M, Doherty DA, Parisi M, <italic toggle="yes">et&#160;al</italic>. Joubert syndrome: ophthalmological findings in correlation with genotype and hepatorenal disease in 99 patients prospectively evaluated at a single center. Ophthalmology. 2018;125:1937&#8211;52.<pub-id pub-id-type="pmid">30055837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2018.05.026</pub-id><pub-id pub-id-type="pmcid">PMC8932443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>SF</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ning</surname><given-names>K</given-names></name><name name-style="western"><surname>Koo</surname><given-names>EB</given-names></name><name name-style="western"><surname>Wu</surname><given-names>AY</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>VB</given-names></name><etal/></person-group><article-title>Review of ocular manifestations of Joubert syndrome</article-title><source>Genes</source><year>2018</year><volume>9</volume><fpage>605</fpage><pub-id pub-id-type="pmid">30518138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes9120605</pub-id><pub-id pub-id-type="pmcid">PMC6315342</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wang SF, Kowal TJ, Ning K, Koo EB, Wu AY, Mahajan VB, <italic toggle="yes">et&#160;al</italic>. Review of ocular manifestations of Joubert syndrome. Genes. 2018;9:605.<pub-id pub-id-type="pmid">30518138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes9120605</pub-id><pub-id pub-id-type="pmcid">PMC6315342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gana</surname><given-names>S</given-names></name><name name-style="western"><surname>Serpieri</surname><given-names>V</given-names></name><name name-style="western"><surname>Valente</surname><given-names>EM</given-names></name></person-group><article-title>Genotype&#8211;phenotype correlates in Joubert syndrome: a review</article-title><source>Am J Med Genet C Semin Med Genet</source><year>2022</year><volume>190</volume><fpage>72</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/ajmg.c.31963</pub-id><pub-id pub-id-type="pmid">35238134</pub-id><pub-id pub-id-type="pmcid">PMC9314610</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Gana S, Serpieri V, Valente EM. Genotype&#8211;phenotype correlates in Joubert syndrome: a review. Am J Med Genet C Semin Med Genet. 2022;190:72&#8211;88. 10.1002/ajmg.c.31963.<pub-id pub-id-type="pmid">35238134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.c.31963</pub-id><pub-id pub-id-type="pmcid">PMC9314610</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuz</surname><given-names>K</given-names></name><name name-style="western"><surname>Bachmann-Gagescu</surname><given-names>R</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>DR</given-names></name><name name-style="western"><surname>Hua</surname><given-names>K</given-names></name><name name-style="western"><surname>Isabella</surname><given-names>CR</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>IG</given-names></name><etal/></person-group><article-title>Mutations in CSPP1 cause primary cilia abnormalities and Joubert syndrome with or without Jeune asphyxiating thoracic dystrophy</article-title><source>Am J Hum Genet</source><year>2014</year><volume>94</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24360808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2013.11.019</pub-id><pub-id pub-id-type="pmcid">PMC3882733</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tuz K, Bachmann-Gagescu R, O&#8217;Day DR, Hua K, Isabella CR, Phelps IG, <italic toggle="yes">et&#160;al</italic>. Mutations in CSPP1 cause primary cilia abnormalities and Joubert syndrome with or without Jeune asphyxiating thoracic dystrophy. Am J Hum Genet. 2014;94:62&#8211;72.<pub-id pub-id-type="pmid">24360808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2013.11.019</pub-id><pub-id pub-id-type="pmcid">PMC3882733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang-Doran</surname><given-names>I</given-names></name><name name-style="western"><surname>Semple</surname><given-names>RK</given-names></name></person-group><article-title>Knockdown of the Alstr&#246;m syndrome-associated gene Alms1 in 3T3-L1 preadipocytes impairs adipogenesis but has no effect on cell-autonomous insulin action</article-title><source>Int J Obes</source><year>2010</year><volume>34</volume><fpage>1554</fpage><lpage>1558</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2010.92</pub-id><pub-id pub-id-type="pmid">20514046</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Huang-Doran I, Semple RK. Knockdown of the Alstr&#246;m syndrome-associated gene Alms1 in 3T3-L1 preadipocytes impairs adipogenesis but has no effect on cell-autonomous insulin action. Int J Obes. 2010;34:1554&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2010.92</pub-id><pub-id pub-id-type="pmid">20514046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butorac Ahel</surname><given-names>I</given-names></name><name name-style="western"><surname>Severinski</surname><given-names>S</given-names></name><name name-style="western"><surname>Lah Tomulic</surname><given-names>K</given-names></name><name name-style="western"><surname>Milardovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Baraba Dekanic</surname><given-names>K</given-names></name><name name-style="western"><surname>Palcevski</surname><given-names>D</given-names></name></person-group><article-title>An extremely high blood glucose level in a child with hyperglycemic hyperosmolar state and type 1 diabetes</article-title><source>J Pediatr Endocrinol Metab</source><year>2021</year><volume>34</volume><fpage>1045</fpage><lpage>1048</lpage><pub-id pub-id-type="pmid">33939902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/jpem-2020-0720</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Butorac Ahel I, Severinski S, Lah Tomulic K, Milardovic A, Baraba Dekanic K, Palcevski D. An extremely high blood glucose level in a child with hyperglycemic hyperosmolar state and type 1 diabetes. J Pediatr Endocrinol Metab. 2021;34:1045&#8211;8.<pub-id pub-id-type="pmid">33939902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/jpem-2020-0720</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penon-Portmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Eldomery</surname><given-names>MK</given-names></name><name name-style="western"><surname>Potocki</surname><given-names>L</given-names></name><name name-style="western"><surname>Marafi</surname><given-names>D</given-names></name><name name-style="western"><surname>Posey</surname><given-names>JE</given-names></name><name name-style="western"><surname>Coban-Akdemir</surname><given-names>Z</given-names></name><etal/></person-group><article-title>De novo heterozygous variants in SLC30A7 are a candidate cause for Joubert syndrome</article-title><source>Am J Med Genet A</source><year>2022</year><volume>188</volume><fpage>2360</fpage><pub-id pub-id-type="pmid">35751429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.a.62872</pub-id><pub-id pub-id-type="pmcid">PMC9756141</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Penon-Portmann M, Eldomery MK, Potocki L, Marafi D, Posey JE, Coban-Akdemir Z, <italic toggle="yes">et&#160;al</italic>. De novo heterozygous variants in SLC30A7 are a candidate cause for Joubert syndrome. Am J Med Genet A. 2022;188:2360.<pub-id pub-id-type="pmid">35751429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.a.62872</pub-id><pub-id pub-id-type="pmcid">PMC9756141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H</given-names></name><name name-style="western"><surname>Jia</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical and genetic characteristics of 36 children with Joubert syndrome</article-title><source>Front Pediatr</source><year>2023</year><volume>11</volume><fpage>1102639</fpage><pub-id pub-id-type="pmid">37547106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2023.1102639</pub-id><pub-id pub-id-type="pmcid">PMC10401045</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dong Y, Zhang K, Yao H, Jia T, Wang J, Zhu D, <italic toggle="yes">et&#160;al</italic>. Clinical and genetic characteristics of 36 children with Joubert syndrome. Front Pediatr. 2023;11:1102639.<pub-id pub-id-type="pmid">37547106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2023.1102639</pub-id><pub-id pub-id-type="pmcid">PMC10401045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schr&#246;der</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yigit</surname><given-names>G</given-names></name><name name-style="western"><surname>Altm&#252;ller</surname><given-names>J</given-names></name><name name-style="western"><surname>Bader</surname><given-names>I</given-names></name><name name-style="western"><surname>Bevot</surname><given-names>A</given-names></name><etal/></person-group><article-title>Heterozygous truncating variants in SUFU cause congenital ocular motor apraxia</article-title><source>Genet Med</source><year>2021</year><volume>23</volume><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">33024317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-020-00979-w</pub-id><pub-id pub-id-type="pmcid">PMC7862056</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Schr&#246;der S, Li Y, Yigit G, Altm&#252;ller J, Bader I, Bevot A, <italic toggle="yes">et&#160;al</italic>. Heterozygous truncating variants in SUFU cause congenital ocular motor apraxia. Genet Med. 2021;23:341&#8211;51.<pub-id pub-id-type="pmid">33024317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-020-00979-w</pub-id><pub-id pub-id-type="pmcid">PMC7862056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Abrusco</surname><given-names>F</given-names></name><name name-style="western"><surname>Serpieri</surname><given-names>V</given-names></name><name name-style="western"><surname>Taccagni</surname><given-names>CM</given-names></name><name name-style="western"><surname>Garau</surname><given-names>J</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>L</given-names></name><name name-style="western"><surname>Boggioni</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pathogenic cryptic variants detectable through exome data reanalysis significantly increase the diagnostic yield in Joubert syndrome</article-title><source>Eur J Hum Genet</source><year>2024</year><volume>33</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">39394465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41431-024-01703-x</pub-id><pub-id pub-id-type="pmcid">PMC11711660</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">D&#8217;Abrusco F, Serpieri V, Taccagni CM, Garau J, Cattaneo L, Boggioni M, <italic toggle="yes">et&#160;al</italic>. Pathogenic cryptic variants detectable through exome data reanalysis significantly increase the diagnostic yield in Joubert syndrome. Eur J Hum Genet. 2024;33:72&#8211;9.<pub-id pub-id-type="pmid">39394465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41431-024-01703-x</pub-id><pub-id pub-id-type="pmcid">PMC11711660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>KR</given-names></name><name name-style="western"><surname>Meeks</surname><given-names>H</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>D</given-names></name><name name-style="western"><surname>Brown</surname><given-names>BB</given-names></name><name name-style="western"><surname>Kole</surname><given-names>K</given-names></name><name name-style="western"><surname>Kowaleski-Jones</surname><given-names>L</given-names></name></person-group><article-title>Family history of type 2 diabetes and the risk of type 2 diabetes among young and middle-aged adults</article-title><source>Chronic Dis Transl Med</source><year>2024</year><volume>11</volume><fpage>46</fpage><pub-id pub-id-type="pmid">40051822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cdt3.147</pub-id><pub-id pub-id-type="pmcid">PMC11880113</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Smith KR, Meeks H, Curtis D, Brown BB, Kole K, Kowaleski-Jones L. Family history of type 2 diabetes and the risk of type 2 diabetes among young and middle-aged adults. Chronic Dis Transl Med. 2024;11:46.<pub-id pub-id-type="pmid">40051822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cdt3.147</pub-id><pub-id pub-id-type="pmcid">PMC11880113</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knop</surname><given-names>MR</given-names></name><name name-style="western"><surname>Geng</surname><given-names>TT</given-names></name><name name-style="western"><surname>Gorny</surname><given-names>AW</given-names></name><name name-style="western"><surname>Ding</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Ley</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Birth weight and risk of type 2 diabetes mellitus, cardiovascular disease, and hypertension in adults: a meta-analysis of 7 646 267 participants from 135 studies</article-title><source>J Am Heart Assoc</source><year>2018</year><pub-id pub-id-type="doi">10.1161/JAHA.118.008870</pub-id><pub-id pub-id-type="pmid">30486715</pub-id><pub-id pub-id-type="pmcid">PMC6405546</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Knop MR, Geng TT, Gorny AW, Ding R, Li C, Ley SH, <italic toggle="yes">et&#160;al</italic>. Birth weight and risk of type 2 diabetes mellitus, cardiovascular disease, and hypertension in adults: a meta-analysis of 7 646 267 participants from 135 studies. J Am Heart Assoc. 2018. 10.1161/JAHA.118.008870.<pub-id pub-id-type="pmid">30486715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.118.008870</pub-id><pub-id pub-id-type="pmcid">PMC6405546</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>